ID   RYR1_MOUSE              Reviewed;        5035 AA.
AC   E9PZQ0; Q60834; Q61779; Q61780; Q62173; Q62196; Q62235; Q78EJ6; Q7TNG1;
AC   Q80UQ5; Q80X16; Q99JF9;
DT   22-FEB-2012, integrated into UniProtKB/Swiss-Prot.
DT   05-APR-2011, sequence version 1.
DT   22-FEB-2023, entry version 95.
DE   RecName: Full=Ryanodine receptor 1;
DE            Short=RYR-1;
DE            Short=RyR1;
DE   AltName: Full=Skeletal muscle calcium release channel;
DE   AltName: Full=Skeletal muscle ryanodine receptor;
DE   AltName: Full=Skeletal muscle-type ryanodine receptor;
DE   AltName: Full=Type 1 ryanodine receptor;
GN   Name=Ryr1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF ILE-4895.
RC   STRAIN=BALB/c X CD-1;
RX   PubMed=18003898; DOI=10.1073/pnas.0709312104;
RA   Zvaritch E., Depreux F., Kraeva N., Loy R.E., Goonasekera S.A.,
RA   Boncompagni S., Kraev A., Gramolini A.O., Dirksen R.T.,
RA   Franzini-Armstrong C., Seidman C.E., Seidman J.G., MacLennan D.H.;
RT   "An Ryr1I4895T mutation abolishes Ca2+ release channel function and delays
RT   development in homozygous offspring of a mutant mouse line.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:18537-18542(2007).
RN   [2]
RP   ERRATUM OF PUBMED:18003898.
RA   Zvaritch E., Depreux F., Kraeva N., Loy R.E., Goonasekera S.A.,
RA   Boncompagni S., Kraev A., Gramolini A.O., Dirksen R.T.,
RA   Franzini-Armstrong C., Seidman C.E., Seidman J.G., MacLennan D.H.;
RL   Proc. Natl. Acad. Sci. U.S.A. 105:825-825(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57, NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1-27, FUNCTION, AND DISRUPTION PHENOTYPE.
RC   STRAIN=129/J, and BALB/cJ; TISSUE=Skeletal muscle;
RX   PubMed=7515481; DOI=10.1038/369556a0;
RA   Takeshima H., Iino M., Takekura H., Nishi M., Kuno J., Minowa O.,
RA   Takano H., Noda T.;
RT   "Excitation-contraction uncoupling and muscular degeneration in mice
RT   lacking functional skeletal muscle ryanodine-receptor gene.";
RL   Nature 369:556-559(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 483-861.
RC   STRAIN=129;
RA   Kathirvel P.;
RT   "Characterisation of the murine Ryr1 gene.";
RL   Thesis (2000), University of Edinburgh, United Kingdom.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4500-5035.
RC   STRAIN=FVB/N-3; TISSUE=Eye, and Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4537-5035, AND TISSUE SPECIFICITY.
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=7876312; DOI=10.1083/jcb.128.5.893;
RA   Giannini G., Conti A., Mammarella S., Scrobogna M., Sorrentino V.;
RT   "The ryanodine receptor/calcium channel genes are widely and differentially
RT   expressed in murine brain and peripheral tissues.";
RL   J. Cell Biol. 128:893-904(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4762-5013.
RC   TISSUE=Brain;
RX   PubMed=7635066; DOI=10.1242/dev.121.7.2233;
RA   Ayabe T., Kopf G.S., Schultz R.M.;
RT   "Regulation of mouse egg activation: presence of ryanodine receptors and
RT   effects of microinjected ryanodine and cyclic ADP ribose on uninseminated
RT   and inseminated eggs.";
RL   Development 121:2233-2244(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4913-5035, FUNCTION, SUBCELLULAR LOCATION,
RP   DOMAIN, ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RC   STRAIN=C57BL/6J; TISSUE=Skeletal muscle;
RX   PubMed=7621815; DOI=10.1002/j.1460-2075.1995.tb07302.x;
RA   Takeshima H., Yamazawa T., Ikemoto T., Takekura H., Nishi M., Noda T.,
RA   Iino M.;
RT   "Ca(2+)-induced Ca2+ release in myocytes from dyspedic mice lacking the
RT   type-1 ryanodine receptor.";
RL   EMBO J. 14:2999-3006(1995).
RN   [10]
RP   SUBCELLULAR LOCATION, MEMBRANE TOPOLOGY, AND DOMAIN.
RX   PubMed=7724570; DOI=10.1073/pnas.92.8.3381;
RA   Takekura H., Nishi M., Noda T., Takeshima H., Franzini-Armstrong C.;
RT   "Abnormal junctions between surface membrane and sarcoplasmic reticulum in
RT   skeletal muscle with a mutation targeted to the ryanodine receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:3381-3385(1995).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION AT SER-2844, S-NITROSYLATION, AND IDENTIFICATION
RP   IN A COMPLEX WITH PDE4D; PKA; FKBP1A AND PROTEIN PHOSPHATASE 1.
RX   PubMed=18268335; DOI=10.1073/pnas.0711074105;
RA   Bellinger A.M., Reiken S., Dura M., Murphy P.W., Deng S.X., Landry D.W.,
RA   Nieman D., Lehnart S.E., Samaru M., LaCampagne A., Marks A.R.;
RT   "Remodeling of ryanodine receptor complex causes 'leaky' channels: a
RT   molecular mechanism for decreased exercise capacity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2198-2202(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2844, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, and Lung;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [13]
RP   FUNCTION IN BRAIN, S-NITROSYLATION, ACTIVITY REGULATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=22036948; DOI=10.1038/emboj.2011.386;
RA   Kakizawa S., Yamazawa T., Chen Y., Ito A., Murayama T., Oyamada H.,
RA   Kurebayashi N., Sato O., Watanabe M., Mori N., Oguchi K., Sakurai T.,
RA   Takeshima H., Saito N., Iino M.;
RT   "Nitric oxide-induced calcium release via ryanodine receptors regulates
RT   neuronal function.";
RL   EMBO J. 31:417-428(2012).
RN   [14]
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   MUTAGENESIS OF ARG-165, AND PHOSPHORYLATION AT SER-2844.
RX   PubMed=21156754; DOI=10.1124/mol.110.067959;
RA   Feng W., Barrientos G.C., Cherednichenko G., Yang T., Padilla I.T.,
RA   Truong K., Allen P.D., Lopez J.R., Pessah I.N.;
RT   "Functional and biochemical properties of ryanodine receptor type 1
RT   channels from heterozygous R163C malignant hyperthermia-susceptible mice.";
RL   Mol. Pharmacol. 79:420-431(2011).
RN   [15]
RP   REVIEW.
RX   PubMed=20214899; DOI=10.1016/j.febslet.2010.03.005;
RA   Kushnir A., Betzenhauser M.J., Marks A.R.;
RT   "Ryanodine receptor studies using genetically engineered mice.";
RL   FEBS Lett. 584:1956-1965(2010).
CC   -!- FUNCTION: Calcium channel that mediates the release of Ca(2+) from the
CC       sarcoplasmic reticulum into the cytoplasm and thereby plays a key role
CC       in triggering muscle contraction following depolarization of T-tubules
CC       (PubMed:18003898, PubMed:7515481, PubMed:7621815, PubMed:21156754).
CC       Repeated very high-level exercise increases the open probability of the
CC       channel and leads to Ca(2+) leaking into the cytoplasm
CC       (PubMed:18268335). Can also mediate the release of Ca(2+) from
CC       intracellular stores in neurons, and may thereby promote prolonged
CC       Ca(2+) signaling in the brain (PubMed:22036948). Required for normal
CC       embryonic development of muscle fibers and skeletal muscle
CC       (PubMed:7515481). Required for normal heart morphogenesis, skin
CC       development and ossification during embryogenesis (PubMed:18003898,
CC       PubMed:7515481). {ECO:0000269|PubMed:18003898,
CC       ECO:0000269|PubMed:18268335, ECO:0000269|PubMed:21156754,
CC       ECO:0000269|PubMed:22036948, ECO:0000269|PubMed:7515481,
CC       ECO:0000269|PubMed:7621815}.
CC   -!- ACTIVITY REGULATION: Channel activity is modulated by the alkaloid
CC       ryanodine that binds to the open Ca-release channel with high affinity.
CC       At low concentrations, ryanodine maintains the channel in an open
CC       conformation. High ryanodine concentrations inhibit channel activity
CC       (PubMed:7621815). Channel activity is regulated by calmodulin (CALM).
CC       The calcium release is activated by increased cytoplasmic calcium
CC       levels, by nitric oxyde (NO), caffeine and ATP (PubMed:7621815,
CC       PubMed:22036948, PubMed:21156754). Channel activity is inhibited by
CC       magnesium ions, possibly by competition for calcium binding sites.
CC       {ECO:0000269|PubMed:21156754, ECO:0000269|PubMed:7621815}.
CC   -!- SUBUNIT: Homotetramer (PubMed:18003898). Can also form heterotetramers
CC       with RYR2 (By similarity). Identified in a complex composed of RYR1,
CC       PDE4D, PKA, FKBP1A and protein phosphatase 1 (PP1) (PubMed:18268335).
CC       Repeated very high-level exercise decreases interaction with PDE4D and
CC       protein phosphatase 1 (PP1) (PubMed:18268335). Interacts with CALM;
CC       CALM with bound calcium inhibits the RYR1 channel activity (By
CC       similarity). Interacts with S100A1 (By similarity). Interacts with
CC       FKBP1A; this stabilizes the closed conformation of the channel.
CC       Interacts with CACNA1S; interaction with CACNA1S is important for
CC       activation of the RYR1 channel. Interacts with CACNB1. Interacts with
CC       TRDN and ASPH; these interactions stimulate RYR1 channel activity.
CC       Interacts with SELENON (By similarity). Interacts with scorpion calcins
CC       (AC P0DPT1; AC P0DM30; AC A0A1L4BJ42; AC P59868; AC P60254; AC B8QG00;
CC       AC L0GBR1; AC P60252; AC P60253) (By similarity).
CC       {ECO:0000250|UniProtKB:P11716, ECO:0000250|UniProtKB:P21817,
CC       ECO:0000269|PubMed:18003898, ECO:0000269|PubMed:18268335}.
CC   -!- INTERACTION:
CC       E9PZQ0; O55108: Bsg; NbExp=3; IntAct=EBI-642079, EBI-643315;
CC       E9PZQ0; P49070: Camlg; NbExp=3; IntAct=EBI-642079, EBI-309114;
CC       E9PZQ0; P26883: Fkbp1a; NbExp=2; IntAct=EBI-642079, EBI-6379901;
CC   -!- SUBCELLULAR LOCATION: Sarcoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:18003898, ECO:0000269|PubMed:7621815}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:18003898}. Membrane {ECO:0000305};
CC       Multi-pass membrane protein {ECO:0000305}. Sarcoplasmic reticulum
CC       {ECO:0000250|UniProtKB:P11716}. Note=The number of predicted
CC       transmembrane domains varies between orthologs, but the 3D-structures
CC       show the presence of six transmembrane regions. Both N-terminus and C-
CC       terminus are cytoplasmic. {ECO:0000250|UniProtKB:P11716}.
CC   -!- TISSUE SPECIFICITY: Detected in muscle and myotubes (at protein level)
CC       (PubMed:18003898). Ubiquitous. Detected in diaphragm, skeletal muscle,
CC       esophagus, spleen, submaxillary gland, adrenal gland, cerebellum, brain
CC       and in testis germ cells. {ECO:0000269|PubMed:18003898,
CC       ECO:0000269|PubMed:21156754, ECO:0000269|PubMed:22036948,
CC       ECO:0000269|PubMed:7621815, ECO:0000269|PubMed:7876312}.
CC   -!- DOMAIN: The calcium release channel activity resides in the C-terminal
CC       region while the remaining part of the protein constitutes the 'foot'
CC       structure spanning the junctional gap between the sarcoplasmic
CC       reticulum (SR) and the T-tubule (PubMed:7621815, PubMed:7724570). Pore
CC       opening is mediated via the cytoplasmic calcium-binding domains that
CC       mediate a small rotation of the channel-forming transmembrane regions
CC       that then leads to channel opening (By similarity).
CC       {ECO:0000250|UniProtKB:P11716, ECO:0000269|PubMed:7621815,
CC       ECO:0000269|PubMed:7724570}.
CC   -!- PTM: Channel activity is modulated by phosphorylation. Phosphorylation
CC       at Ser-2844 may increase channel activity. Repeated very high-level
CC       exercise increases phosphorylation at Ser-2844.
CC       {ECO:0000269|PubMed:18268335, ECO:0000269|PubMed:21156754}.
CC   -!- PTM: Activated by reversible S-nitrosylation (PubMed:22036948).
CC       Repeated very high-level exercise increases S-nitrosylation.
CC       {ECO:0000250, ECO:0000269|PubMed:18268335,
CC       ECO:0000269|PubMed:22036948}.
CC   -!- DISRUPTION PHENOTYPE: Perinatal lethality, due to severe defects in
CC       skeletal muscle development. Neonates do not breathe and do not move.
CC       Mutant mice show defects in muscle fiber development. Their muscles do
CC       not show a contractile response to electrical stimulation. In addition,
CC       mice display abnormal curvature of the spine, thin limbs, and an
CC       abnormal rib cage. {ECO:0000269|PubMed:7515481}.
CC   -!- SIMILARITY: Belongs to the ryanodine receptor (TC 1.A.3.1) family. RYR1
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY268935; AAP29981.1; -; mRNA.
DR   EMBL; AC164564; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC165142; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; D21798; BAA21010.1; -; Genomic_DNA.
DR   EMBL; D21796; BAA04821.1; -; mRNA.
DR   EMBL; D21797; BAA04822.1; -; Genomic_DNA.
DR   EMBL; AJ308737; CAC34624.1; -; Genomic_DNA.
DR   EMBL; BC051248; AAH51248.1; -; mRNA.
DR   EMBL; BC055487; AAH55487.1; -; mRNA.
DR   EMBL; X83932; CAA58784.1; -; mRNA.
DR   EMBL; U23754; AAA64955.1; -; mRNA.
DR   EMBL; D38216; BAA07391.1; -; mRNA.
DR   CCDS; CCDS39866.1; -.
DR   PIR; I48741; I48741.
DR   PIR; I58087; I58087.
DR   PIR; I78376; I78376.
DR   PIR; I78377; I78377.
DR   PIR; S56105; S56105.
DR   RefSeq; NP_033135.2; NM_009109.2.
DR   SMR; E9PZQ0; -.
DR   BioGRID; 203045; 10.
DR   ComplexPortal; CPX-3092; Ryanodine 1 complex.
DR   DIP; DIP-29705N; -.
DR   IntAct; E9PZQ0; 29.
DR   MINT; E9PZQ0; -.
DR   STRING; 10090.ENSMUSP00000137123; -.
DR   BindingDB; E9PZQ0; -.
DR   ChEMBL; CHEMBL2133; -.
DR   iPTMnet; E9PZQ0; -.
DR   PhosphoSitePlus; E9PZQ0; -.
DR   MaxQB; E9PZQ0; -.
DR   PaxDb; E9PZQ0; -.
DR   PeptideAtlas; E9PZQ0; -.
DR   ProteomicsDB; 256854; -.
DR   Antibodypedia; 44914; 178 antibodies from 25 providers.
DR   DNASU; 20190; -.
DR   Ensembl; ENSMUST00000179893.9; ENSMUSP00000137123.2; ENSMUSG00000030592.19.
DR   GeneID; 20190; -.
DR   KEGG; mmu:20190; -.
DR   UCSC; uc009gao.1; mouse.
DR   AGR; MGI:99659; -.
DR   CTD; 6261; -.
DR   MGI; MGI:99659; Ryr1.
DR   VEuPathDB; HostDB:ENSMUSG00000030592; -.
DR   eggNOG; KOG2243; Eukaryota.
DR   GeneTree; ENSGT00940000155288; -.
DR   InParanoid; E9PZQ0; -.
DR   OrthoDB; 3144451at2759; -.
DR   PhylomeDB; E9PZQ0; -.
DR   TreeFam; TF315244; -.
DR   Reactome; R-MMU-2672351; Stimuli-sensing channels.
DR   Reactome; R-MMU-5578775; Ion homeostasis.
DR   BioGRID-ORCS; 20190; 2 hits in 78 CRISPR screens.
DR   ChiTaRS; Ryr1; mouse.
DR   PRO; PR:E9PZQ0; -.
DR   Proteomes; UP000000589; Chromosome 7.
DR   RNAct; E9PZQ0; protein.
DR   Bgee; ENSMUSG00000030592; Expressed in triceps brachii and 115 other tissues.
DR   ExpressionAtlas; E9PZQ0; baseline and differential.
DR   Genevisible; E9PZQ0; MM.
DR   GO; GO:0034704; C:calcium channel complex; IBA:GO_Central.
DR   GO; GO:0005938; C:cell cortex; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IBA:GO_Central.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; ISO:MGI.
DR   GO; GO:0031674; C:I band; ISO:MGI.
DR   GO; GO:0030314; C:junctional membrane complex; IDA:MGI.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0031090; C:organelle membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:1990425; C:ryanodine receptor complex; ISS:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; ISO:MGI.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IDA:MGI.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0030315; C:T-tubule; IDA:MGI.
DR   GO; GO:0014802; C:terminal cisterna; ISS:UniProtKB.
DR   GO; GO:0030018; C:Z disc; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0005262; F:calcium channel activity; IMP:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0048763; F:calcium-induced calcium release activity; ISO:MGI.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0005219; F:ryanodine-sensitive calcium-release channel activity; IMP:UniProtKB.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IDA:MGI.
DR   GO; GO:0071318; P:cellular response to ATP; ISO:MGI.
DR   GO; GO:0071313; P:cellular response to caffeine; IMP:UniProtKB.
DR   GO; GO:0071277; P:cellular response to calcium ion; ISS:UniProtKB.
DR   GO; GO:0006936; P:muscle contraction; IDA:MGI.
DR   GO; GO:0043931; P:ossification involved in bone maturation; IMP:UniProtKB.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IMP:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISO:MGI.
DR   GO; GO:0006937; P:regulation of muscle contraction; TAS:MGI.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IMP:MGI.
DR   GO; GO:0014808; P:release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; IMP:UniProtKB.
DR   GO; GO:0031000; P:response to caffeine; ISO:MGI.
DR   GO; GO:0001666; P:response to hypoxia; ISO:MGI.
DR   GO; GO:0070296; P:sarcoplasmic reticulum calcium ion transport; ISO:MGI.
DR   GO; GO:0048741; P:skeletal muscle fiber development; IMP:UniProtKB.
DR   GO; GO:0043588; P:skin development; IMP:UniProtKB.
DR   CDD; cd12877; SPRY1_RyR; 1.
DR   CDD; cd12878; SPRY2_RyR; 1.
DR   CDD; cd12879; SPRY3_RyR; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.10.490.160; -; 2.
DR   Gene3D; 2.60.120.920; -; 3.
DR   Gene3D; 2.80.10.50; -; 2.
DR   Gene3D; 6.20.350.10; -; 1.
DR   Gene3D; 1.25.10.30; IP3 receptor type 1 binding core, RIH domain; 1.
DR   InterPro; IPR001870; B30.2/SPRY.
DR   InterPro; IPR043136; B30.2/SPRY_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR014821; Ins145_P3_rcpt.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR036300; MIR_dom_sf.
DR   InterPro; IPR016093; MIR_motif.
DR   InterPro; IPR013662; RIH_assoc-dom.
DR   InterPro; IPR000699; RIH_dom.
DR   InterPro; IPR013333; Ryan_recept.
DR   InterPro; IPR015925; Ryanodine_IP3_receptor.
DR   InterPro; IPR003032; Ryanodine_rcpt.
DR   InterPro; IPR009460; Ryanrecept_TM4-6.
DR   InterPro; IPR035910; RyR/IP3R_RIH_dom_sf.
DR   InterPro; IPR035761; SPRY1_RyR.
DR   InterPro; IPR035764; SPRY2_RyR.
DR   InterPro; IPR035762; SPRY3_RyR.
DR   InterPro; IPR003877; SPRY_dom.
DR   PANTHER; PTHR46399; B30.2/SPRY DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR46399:SF10; RYANODINE RECEPTOR 1; 1.
DR   Pfam; PF08709; Ins145_P3_rec; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF02815; MIR; 1.
DR   Pfam; PF08454; RIH_assoc; 1.
DR   Pfam; PF06459; RR_TM4-6; 1.
DR   Pfam; PF01365; RYDR_ITPR; 2.
DR   Pfam; PF02026; RyR; 4.
DR   Pfam; PF00622; SPRY; 3.
DR   PRINTS; PR00795; RYANODINER.
DR   SMART; SM00472; MIR; 4.
DR   SMART; SM00449; SPRY; 3.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 3.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF100909; IP3 receptor type 1 binding core, domain 2; 2.
DR   SUPFAM; SSF82109; MIR domain; 2.
DR   PROSITE; PS50188; B302_SPRY; 3.
DR   PROSITE; PS50919; MIR; 5.
PE   1: Evidence at protein level;
KW   ATP-binding; Calcium; Calcium channel; Calcium transport;
KW   Calmodulin-binding; Developmental protein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; S-nitrosylation;
KW   Sarcoplasmic reticulum; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..5035
FT                   /note="Ryanodine receptor 1"
FT                   /id="PRO_0000415566"
FT   TOPO_DOM        1..4556
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4557..4577
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4578..4638
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4639..4659
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4660..4777
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4778..4800
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4801
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4802..4818
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4819..4833
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4834..4854
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4855..4877
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   INTRAMEM        4878..4897
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4898..4917
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4918..4938
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4939..5035
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   DOMAIN          99..154
FT                   /note="MIR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          161..206
FT                   /note="MIR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          212..266
FT                   /note="MIR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          272..329
FT                   /note="MIR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          337..394
FT                   /note="MIR 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          583..799
FT                   /note="B30.2/SPRY 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          843..956
FT                   /note="1"
FT   REPEAT          957..1070
FT                   /note="2"
FT   DOMAIN          1015..1210
FT                   /note="B30.2/SPRY 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          1346..1361
FT                   /note="3; truncated"
FT   DOMAIN          1359..1572
FT                   /note="B30.2/SPRY 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          1374..1389
FT                   /note="4; truncated"
FT   REPEAT          2727..2846
FT                   /note="5"
FT   REPEAT          2847..2960
FT                   /note="6"
FT   DOMAIN          4078..4106
FT                   /note="EF-hand"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   REGION          671..682
FT                   /note="Interaction with FKBP1A"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   REGION          843..2960
FT                   /note="6 X approximate repeats"
FT   REGION          1309..1387
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1873..1928
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2391..2414
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2828..2859
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3479..3502
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3615..3644
FT                   /note="Interaction with CALM"
FT                   /evidence="ECO:0000250"
FT   REGION          4255..4283
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4378..4531
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4586..4618
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           4892..4898
FT                   /note="Selectivity filter"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   COMPBIAS        1372..1387
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1874..1923
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2828..2844
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4257..4274
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4402..4418
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4482..4496
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4497..4513
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4514..4528
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         3896
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         3970
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4214..4218
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4714
FT                   /ligand="caffeine"
FT                   /ligand_id="ChEBI:CHEBI:27732"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4952..4957
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4977..4983
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4999
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   MOD_RES         1339
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         2346
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         2844
FT                   /note="Phosphoserine; by PKA and PKG"
FT                   /evidence="ECO:0000269|PubMed:18268335,
FT                   ECO:0000269|PubMed:21156754, ECO:0007744|PubMed:21183079"
FT   MOD_RES         3636
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   MOD_RES         4464
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         4468
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         4861
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P21817"
FT   MOD_RES         4864
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P21817"
FT   MUTAGEN         165
FT                   /note="R->C: Increased channel activity, leading to
FT                   permanently increased cytoplasmic Ca(2+) levels. Increased
FT                   activation by calcium, and increased ryanodine binding."
FT                   /evidence="ECO:0000269|PubMed:21156754"
FT   MUTAGEN         4895
FT                   /note="I->T: Causes paralysis and perinatal death in
FT                   homozygous mice, apparently due to asphyxia. Mutant mice
FT                   have greatly reduced and amorphous skeletal muscle."
FT                   /evidence="ECO:0000269|PubMed:18003898"
FT   CONFLICT        616
FT                   /note="R -> C (in Ref. 5; CAC34624)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1380
FT                   /note="A -> S (in Ref. 1; AAP29981)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3484
FT                   /note="D -> V (in Ref. 1; AAP29981)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4766
FT                   /note="I -> L (in Ref. 8; AAA64955)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4821
FT                   /note="L -> V (in Ref. 7; CAA58784)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4888
FT                   /note="G -> A (in Ref. 7; CAA58784)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   5035 AA;  565039 MW;  D15D2E764B445573 CRC64;
     MGDGGGEGED EVQFLRTDDE VVLQCSATVL KEQLKLCLAA EGFGNRLCFL EPTSNAQNVP
     PDLAICCFIL EQSLSVRALQ EMLANTVEAG VESSQGGGHR TLLYGHAILL RHAHSRMYLS
     CLTTSRSMTD KLAFDVGLQE DATGEACWWT MHPASKQRSE GEKVRVGDDL ILVSVSSERY
     LHLSTASGEL QVDASFMQTL WNMNPICSGC EEGFVTGGHV LRLFHGHMDE CLTISPSDSD
     DQRRLVYYEG GPVCTHARSL WRLEPLRISW SGSHLRWGQP LRIRHVTTGR YLGLTEDQGL
     VVVDASKAHT KATSFCFRIS KEKLDVAPKR DVEGMGPPEI KYGESLCFVQ HVASGLWLTY
     AAPDPKALRL GVLKKKAMLH QEGHMDDALS LTRCQQEESQ AARMIYSTAG LYNQFIKGLD
     SFSGKPRGSG PPAGSALPIE GVILSLQDLI GYFEPPSEEL QHEEKQTKLR SLRNRQSLFQ
     EEGMLSLVLN CIDRLNVYTT AAHFAEFAGE EAAESWKEIV NLLYELLASL IRGNRTNCAL
     FSTNLDWLVS KLDRLEASSG ILEVLYCVLI ESPEVLNIIQ ENHIKSIISL LDKHGRNHKV
     LDVLCSLCVC NGVAVRSNQD LITENLLPGR ELLLQTNLIN YVTSIRPNIF VGRAEGSTQY
     GKWYFEVMVD EVAPFLTAQA THLRVGWALS EGYSPYPGGG EGWGGNGVGD DLYSYGFDGL
     HLWTGHVARP VTSPGQHLLA PEDVVSCCLD LSVPSISFRI NGCPVQGVFE SFNLDGLFFP
     VVSFSAGIKV RFLLGGRHGE FKFLPPPGYA PCHEAVLPRE RLHLQPIKEY RREGPRGPHL
     VGPSRCLSHL DFVPCPVDTI QIVLPPHLER IREKLAENIH ELWALTRIEQ GWTYGPVRDD
     NKRLHPCLVN FHSLPEPERN YNLQMSGETL KTLLALGCHV GMADEKAEDN LKKTKLPKTY
     MMSNGYKPAP LDLSHVRLTP AQTTLVDRLA ENGHNVWARD RVAQGWSYSA VQDIPARRNP
     RLVPYRLLDE ATKRSNRDSL CQAVRTLLGY GYNIEPPDQE PSQVDSQSRG DRARIFRAEK
     SYAVQSGRWY FEFEAVTTGE MRVGWARPEL RPDVELGADD LAYVFNGHRG QRWHLGSEPF
     GRPWQSGDVV GCMIDLTENT IIFTLNGEVL MSDSGSETAF RDIEIGDGFL PVCSLGPGQV
     GHLNLGQDVS SLRFFAICGL QEGFEPFAIN MQRPVTTWFS KSLPQFEPVP LEHPHYEVAR
     MDGTVDTPPC LRLTHRTWGS QNSLVEMLFL RLSLPVQFHQ HFRCTAGATP LASPGLQPPA
     EDEARAAEPD TDYENLRRSA GGWGEAEGGK DGTAKEGTPG GTAQAGVEAQ PARAENEKDA
     TTEKNKKRGF LFKAKKVAMM TQPPSTPALP RLPRDVVPAD NRDDPEIILN TTTYYYSVRV
     FAGQEPSCVW VGWVTPDYHQ HDMSFDLSKV RAVTVTMGDE QGNVHSSLKC SNCYMVWGGD
     FVSPGQQGRI SHTDLVIGCL VDLATGLMTF TANGKESNTF FQVEPNTKLF PAVFVLPTHQ
     NVVQFELGKQ KNIMPLSAAM FLSERKNPAP QCPPRLEVQM LMPVSWSRMP NHFLQVDTRR
     AGERLGWAVQ CQEPLMMMAL HIPEENRCMD ILELSERLDL QRFHSHTLSL YRSVCALGNN
     RVAHALCSHV DQAQLLHALE DARLPGPLRA GYYDLLISIH LESACRSRRS MLSEYIVPLT
     PETRAITLFP PGRSAEDGPR RHGLPGVGVT TSLRPPHHFS PPCFVVALPA AGATEAPARL
     SPAIPLEALR DKALRMLGEA VRDGGQHARD PVGGSVEFQF VPVLKLVSTL LVMGVFSDED
     VKQILKMIEP EVFREEEEVE EEGEEEEEDE EEKEEDEEEE AHEKEDEEKE EAEDAAEEEK
     EELEEGLLQM KLPESVKLQM CHLLEYFCDQ ELQHRVESLA AFAECYVDKM QGNQRGRYGL
     LMKAFTMSAA ETARRTREFR SPPQEQINML LHFKNGADEE ECPLPEEIRQ ELVNFHQDLL
     AHCGIQLEGE EEEPEEESTL GSRLMSLLEK VKLVKKTEEK PEEEPAPEEH KPQSLQELVS
     HTVVRWAQED FVQSPELVRA MFSLLHRQYD GLGELLRALP RAYTISVSSV EDTMSLLECL
     GQIRSLLIVQ MGPQEENLMI QSIGNIMNNK VFYQHPNLMR ALGMHETVME VMVNVLGGGE
     SKEIRFPKMV TSCCRFLCYF CRISRQNQRS MFDHLSYLLE NSGIGLGMQG STPLDVAAAS
     VIDNNELALA LQEQDLEKVV SYLAGCGLQS CPMLLAKGYP DIGWNPCGGE RYLDFLRFAV
     FVNGESVEEN ANVVVRLLIR KPECFGPALR GEGGSGLLAA IEEAIRISED PARDGPGVRR
     DRRREHFGEE PPEENRVHLG HAIMSFYAAL IDLLGRCAPE THLIQAGKGE ALRIRAILRS
     LVPLDDLVGI ISLPLQIPTL GKDGALVQPK MSASFVPDHK ASMVLFLDRV YGIENQDFLL
     HVLDVGFLPD MRAAASLDTA TFSTTEMALA LNRYLCLAVL PLITKCAPLF AGTEHRAIMV
     DSMLHTVYRL SRGRSLTKAQ RDVIEDCLMA LCRYIRPSML QHLLRRLVFD VPILNEFAKM
     PLKLLTNHYE RCWKYYCLPT GWANFGVTSE EELHLTRKLF WGIFDSLAHK KYDQELYRIA
     MPCLCAIAGA LPPDYVDASY SSKTEKKATV DAEGNFDPRP VETLNVIIPE KLDSFINKFA
     EYTHEKWAFD KIQNNWSYGE NIDEELKTHP MLRPYKTFSE KDKEIYRWPI KESLKAMIAW
     EWTVEKAREG EEEKTEKKKT RKISQTAQTY DPREGYNPQP PDLSVVTLSR ELQAMAEQLA
     ENYHNTWGRK KKQELEAKGG GSHPLLVPYD TLTAKEKARD REKAQELLKF LQMNGYAVTR
     GLKDMELDTS SIEKRFAFGF LQQLLRWMDI SQEFIAHLEA VVSSGRVEKS PHEQEIKFFA
     KILLPLINQY FTNHCLYFLS TPAKVLGSGG HASNKEKEMI TSLFCKLAAL VRHRVSLFGT
     DAPAVVNCLH ILARSLDART VMKSGPEIVK AGLRSFFESA SEDIEKMVEN LRLGKVSQAR
     TQVKGVGQNL TYTTVALLPV LTTLFQHIAQ HQFGDDVILD DVQVSCYRTL CSIYSLGTTR
     NPYVEKLRPA LGECLARLAA AMPVAFLEPE LNEYNACSVY TTKSPRERAI LGLPNSVEEM
     CPDIPVLERL MAEIGGLAES GARYTEMPHV IEITLPMLCS YLPRWWERGP EAPPPALPAG
     APPPCTAVTS DHLNSLLGNI LRIIVNNLGI DEASWMKRLA VFAQPIVSRA RPELLRSHFI
     PTIGRLRKRA GKVVAEEEQL RLEAKAEAEE GELLVRDEFS VLCRDLYALY PLLIRYVDNN
     RAHWLTEPNP NAEELFRMVG EIFIYWSKSH NFKREEQNFV VQNEINNMSF LTADNKSKMA
     KAGDVQSGGS DQERTKKKRR GDRYSVQTSL IVATLKKMLP IGLNMCAPTD QDLIVLAKAR
     YALKDTDEEV REFLQNNLNL QGKVEGSPSL RWQMALYRGV PGREEDADDP EKIVRRVQEV
     SAVLYHLDQT EHPYKSKKAV WHKLLSKQRR RAVVACFRMT PLYNLPTHRA CNMFLESYKA
     SWILTEDHSF EDRMIDDLSK AGEQEEEEEE VEEKKPDPLH QLVLHFSRTA LTEKSKLDED
     YLYMAYADIM AKSCHLEEGG ENGEEGGEEE EVEVSFEEKE MEKQRLLYQQ SRLHNRGAAE
     MVLQMISACK GETGAMVSST LKLGISILNG GNAEVQQKML DYLKDKKEVG FFQSIQALMQ
     TCSVLDLNAF ERQNKAEGLG MVNEDGTVIN RQNGEKVMAD DEFTQDLFRF LQLLCEGHNN
     DFQNYLRTQT GNTTTINIII CTVDYLLRLQ ESISDFYWYY SGKDVIEEQG KRNFSKAMSV
     AKQVFNSLTE YIQGPCTGNQ QSLAHSRLWD AVVGFLHVFA HMMMKLAQDS SQIELLKELL
     DLQKDMVVML LSLLEGNVVN GMIARQMVDM LVESSSNVEM ILKFFDMFLK LKDIVGSEAF
     QDYVTDPRGL ISKKDFQKAM DSQKQFTGPE IQFLLSCSEA DENEMINCEE FANRFQEPAR
     DIGFNVAVLL TNLSEHVPHD PRLRNFLELA ESILEYFRPY LGRIEIMGAS RRIERIYFEI
     SETNRAQWEM PQVKESKRQF IFDVVNEGGE SEKMEMFVSF CEDTIFEMQI AAQISEPEGE
     PEEDEDEGAE EAEEGAAGSD GSGSAAAAGV WVWLAATAGR TLRGLSYRSL RRRVRRLRRL
     TAREAATAVA ALLWALVTRA GGAGAGAAAG ALRLLWGSLF GGGLVDSAKK VTVTELLAGM
     PDPTGDEVHG QQPSGAGSDA EGEGEGEGEG DAADGAGDEE AAADQAGTGG ADGAVAVADG
     SPFRPEGAGG LGDMGDTTPV EPPTPEGSPI LKRKLGVDGE EEEPPPEPEP EPEPEPEKAD
     TENGEKEVPE PPPEPPKKTP PPPPPKKEEA GGAGLEEFWG ELEVQRVKFL NYLSRNFYTL
     RFLALFLAFA INFILLFYKV SDSPPGEDDI EGSGAGDMSG AGSGDGSGWG SRAGEEVEGD
     EDENMVYYFL EESTGYMEPA LRCLSLLHTL VAFLCIIGYN CLKVPLVIFK REKELARKLE
     FDGLYITEQP EDDDVKGQWD RLVLNTPSFP SNYWDKFVKR KVLDKHGDIF GRERIAELLG
     MDLASLEITA HNERKPDPPP GLLTWIMSID VKYQIWKFGV IFTDNSFLYL GWYMVMSLLG
     HYNNFFFAAH LLDIAMGVKT LRTILSSVTH NGKQLVMTVG LLAVVVYLYT VVAFNFFRKF
     YNKSEDEDEP DMKCDDMMTC YLFHMYVGVR AGGGIGDEIE DPAGDEYELY RVVFDITFFF
     FVIVILLAII QGLIIDAFGE LRDQQEQVKE DMETKCFICG IGSDYFDTTP HGFETHTLEE
     HNLANYMFFL MYLINKDETE HTGQESYVWK MYQERCWDFF PAGDCFRKQY EDQLS
//
